STRO
Sutro Biopharma Inc

1,126
Mkt Cap
$76.67M
Volume
59,628.00
52W High
$24.80
52W Low
$5.23
PE Ratio
-0.35
STRO Fundamentals
Price
$9.74
Prev Close
$9.00
Open
$8.99
50D MA
$9.25
Beta
1.43
Avg. Volume
73,679.95
EPS (Annual)
-$29.61
P/B
-0.88
Rev/Employee
$183,559.17
Loading...
Loading...
News
all
press releases
Velan Capital Investment Management LP Acquires 2,030,000 Shares of Sutro Biopharma, Inc. $STRO
Velan Capital Investment Management LP lifted its stake in Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) by 197.1% during the second quarter, according to the company in its most recent 13F...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from Brokerages
Shares of Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) have received a consensus recommendation of "Hold" from the eight research firms that are currently covering the stock, MarketBeat...
MarketBeat·4d ago
News Placeholder
Sutro Biopharma (NASDAQ:STRO) Shares Gap Down - What's Next?
Sutro Biopharma (NASDAQ:STRO) Shares Gap Down - Time to Sell...
MarketBeat·6d ago
News Placeholder
Sutro Biopharma (NASDAQ:STRO) Shares Gap Up - What's Next?
Sutro Biopharma (NASDAQ:STRO) Shares Gap Up - Time to Buy...
MarketBeat·7d ago
News Placeholder
Sutro Biopharma (NASDAQ:STRO) Receives "Neutral" Rating from Wedbush
Wedbush reiterated a "neutral" rating and set a $10.00 price objective (up previously from $2.00) on shares of Sutro Biopharma in a research report on Tuesday...
MarketBeat·8d ago
News Placeholder
Sutro Biopharma Sets 1-for-10 Reverse Stock Split
(RTTNews) - Sutro Biopharma, Inc. (STRO), a clinical stage oncology company, Monday announced that it has approved a 1-for-10 reverse stock split of its common stock...
Nasdaq News: Markets·10d ago
News Placeholder
FY2028 EPS Estimates for Sutro Biopharma Raised by Analyst
Sutro Biopharma, Inc. (NASDAQ:STRO - Free Report) - Stock analysts at Wedbush lifted their FY2028 earnings per share (EPS) estimates for shares of Sutro Biopharma in a research note issued to...
MarketBeat·23d ago
News Placeholder
Sutro Biopharma's (STRO) Neutral Rating Reaffirmed at Wedbush
Wedbush restated a "neutral" rating and issued a $2.00 target price on shares of Sutro Biopharma in a research note on Friday...
MarketBeat·1mo ago
News Placeholder
Wall Street Zen Downgrades Sutro Biopharma (NASDAQ:STRO) to Sell
Wall Street Zen cut Sutro Biopharma from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·1mo ago
News Placeholder
Sutro Biopharma (NASDAQ:STRO) Releases Quarterly Earnings Results, Misses Expectations By $0.28 EPS
Sutro Biopharma (NASDAQ:STRO - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of...
MarketBeat·1mo ago

Latest STRO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.